💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Piramal Pharma Limited is a global pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. It operates approximately 17 development and manufacturing facilities across India, the United…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak business.
Piramal Pharma is scored on the pharma / healthcare framework. It keeps a thin -3.6% of every rupee of sales as net profit. Free cash flow is worth about 2.6% of its market value.
Book value has grown 6%/yr. Return on equity is a weak -0.8%.
It trades at -152× earnings. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | -152.36 | — | — |
| P/B | 3.91 | 4.1 | better |
| EV/EBITDA | 29.45 | 19.33 | worse |
| ROE | -0.79 | 0.3 | worse |
| ROCE | 4.16 | 14.41 | worse |
| ROA | -1.13 | 1.64 | worse |
| Quick Ratio | 0.87 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue is on a 2-year growth streak. 8% CAGR — growing but slowly. Growth is decelerating — latest year grew slower than the year before.
2 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a -458% swing — check if it's a one-off or structural.
Operating margins have been stable around -2% — no major structural shift.
Negative ROE — the business is destroying shareholder value.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (411% vs 393%) — share dilution is eroding per-share value. 393% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 12% sequentially — momentum is building.
3 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 107% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (-6% → 0%) — profitability per rupee of revenue is improving.
P/E band unavailable — needs 5y of consistent EPS + price history.
Promoters at 34.8% — dispersed ownership; institutional flows drive the stock. FIIs trimmed 16.0pp — foreign money is rotating out.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.